Effective Treatment of NSCLC with Surgery After Nivolumab Combined with Chemotherapy: A Case Report and Brief Review of the Literature

Zhao, Liangchen; Li, Lu-Zhen; Chen, Ting; Fang, Cong

doi:10.2147/ott.s266155

Cited by 3 publications

(2 citation statements)

References 13 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maybe, with this emerging literature on this subject, and these impressive results, we could consider surgery as an adjuvant treatment and not only as a "salvage strategy" for patients priorly treated by a full regimen of chemotherapy with targeted therapy or immunotherapy [164][165][166]. These rare cases need to be discussed in multidisciplinary meeting with expert teams.…”

Section: Resecting After Innovative Systemic Treatment Future Perspectivesmentioning

confidence: 99%

The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

Montagne

Guisier

Vénissac

et al. 2021

Cancers

View full text Add to dashboard Cite

Non-small cell lung cancers (NSCLC) are different today, due to the increased use of screening programs and of innovative systemic therapies, leading to the diagnosis of earlier and pre-invasive tumors, and of more advanced and controlled metastatic tumors. Surgery for NSCLC remains the cornerstone treatment when it can be performed. The role of surgery and surgeons has also evolved because surgeons not only perform the initial curative lung cancer resection but they also accompany and follow-up patients from pre-operative rehabilitation, to treatment for recurrences. Surgery is personalized, according to cancer characteristics, including cancer extensions, from pre-invasive and local tumors to locally advanced, metastatic disease, or residual disease after medical treatment, anticipating recurrences, and patients’ characteristics. Surgical management is constantly evolving to offer the best oncologic resection adapted to each NSCLC stage. Today, NSCLC can be considered as a chronic disease and surgery is a valuable tool for the diagnosis and treatment of recurrences, and in palliative conditions to relieve dyspnea and improve patients’ comfort.

show abstract

Section: Resecting After Innovative Systemic Treatment Future Perspectivesmentioning

confidence: 99%

The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

Montagne

Guisier

Vénissac

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…In fact, surgery can prolong the lifespan of patients with early and locally advanced cancer to a certain degree; however, the effect of surgery is limited. 1 Large-scale gene detection has identified different driver gene mutations in the subtypes of non-small cell lung cancer (NSCLC), which has resulted in several achievements in the development of molecular targeted therapies for lung cancer in recent years. 2 Several previous literature reports reveal that molecular targeted therapy can produce a good therapeutic effect in patients with corresponding gene mutations.…”

Section: Introductionmentioning

confidence: 99%

Cancer Metastases from Lung Adenocarcinoma Disappeared After Molecular Targeted Therapy: A Successfully Clinical Treatment Experience

Li¹,

Wei²,

Ai³

et al. 2022

PGPM

View full text Add to dashboard Cite

Introduction Molecular targeted therapy has shown certain therapeutic effects on various cancer types, especially lung cancer. Here, we report a case of a patient with unresectable non-small cell lung cancer (NSCLC) with bone metastases and metastatic lesions that disappeared after molecular targeted therapy. Patient Information A 49-year-old male patient’s chest CT scan showed a patchy, slightly high-density shadow on the upper lobe of the left lung with an unclear boundary. The multiple thoracic vertebrae, 4th lumbar vertebrae, multiple ribs, right sacroiliac joint, right hip joint, right inferior ramus of pubis, left middle and upper femur, and right proximal radial bone showed nodular and slightly high-density shadows. Interventions The patient was not considered eligible for tumor resection due to his metastatic lesions. A resected lymph node biopsy was performed. The pathologic findings suggested lung adenocarcinoma, and the gene detection results indicated NM-005228:exon19:c.2235–2249del:p. GLu746-Ala750del (15.31%), NM-005228:exon20:c. G2356A: p. V786M (1.67%). The patient received the icotinib hydrochloride molecular targeted therapy. Outcomes After two months of treatment, pulmonary nodules were basically absent on chest CT scan re-examination. After nine months of treatment, no obvious abnormalities in the thoracic vertebral bone were found on 99mTc-MDP bone scan and CT scan re-examination. No obvious structural abnormalities, such as enlarged lymph nodes, could be found by ultrasound re-examination, and the patient remained alive without recurrence at the five-year follow-up. Conclusion This case report may provide a clue for the future development of molecular targeted therapy for lung cancer. It will allow surgeons to collaborate with oncologists and raise awareness of the benefit of the multidisciplinary approach to the diagnosis and treatment of cancer. Moreover, our results will help patients to fully understand the effect of nonsurgical treatments and improve confidence in the diagnosis and treatment of advanced lung cancer.

show abstract

Confining Prepared Ultrasmall Nanozymes Loading ATO for Lung Cancer Catalytic Therapy/Immunotherapy

Zhang,

Gao,

Zhou

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Nanozymes with inherent enzyme‐mimic catalytic properties combat malignant tumor progression via catalytic therapy, while the therapeutic efficacy still needs to be improved. In this work, we innovatively synthesized ultra‐small platinum nanozymes (nPt) in confined domain of wormlike pore channel in gold nanobipyramidal‐mesoporous silica dioxide nanocomposites, producing nanozyme carriers AP‐mSi with photo‐enhanced peroxidase ability. Afterwards, based on the prepared AP‐mSi, the lung cancer nanozymes probe (AP‐HAI) was ingeniously produced by removing SiO2 template, modifying HSA, and loading ATO as well as IR780. Under NIR light irradiation, inner AuP and IR780 collaborated for photothermal process, thus facilitating the peroxidase‐like catalytic process of H2O2. Additionally, loaded atovaquone molecules (ATO), a cell respiration inhibitor, could impair tumor respiration metabolism and cause oxygen retention, hence enhancing IR780's PDT effectiveness. In a result, IR780's PDT property and nPt nanozymes' photo‐enhanced peroxidase‐like ability endowed probes a high ROS productivity, eliciting anti‐tumor immune responses to destroy tumor tissue. Systematic studies revealed that the obvious ROS generation was obtained by the strategy of using nPt nanozymes and reducing oxygen consumption by ATO, which in turn enabled lung cancer synergetic catalytic therapy/ICD‐based immunotherapy. The results of this work would provide theoretical justification for the practical use of photo‐enhanced nanozyme probes.This article is protected by copyright. All rights reserved

show abstract

Effective Treatment of NSCLC with Surgery After Nivolumab Combined with Chemotherapy: A Case Report and Brief Review of the Literature

Cited by 3 publications

References 13 publications

The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives—State of the Art

Cancer Metastases from Lung Adenocarcinoma Disappeared After Molecular Targeted Therapy: A Successfully Clinical Treatment Experience

Confining Prepared Ultrasmall Nanozymes Loading ATO for Lung Cancer Catalytic Therapy/Immunotherapy

Contact Info

Product

Resources

About